Are you the publisher? Claim or contact us about this channel


Embed this content in your HTML

Search

Report adult content:

click to rate:

Account: (login)

More Channels


Channel Catalog


Channel Description:

Daily news and press releases about Healthcare

older | 1 | .... | 1098 | 1099 | (Page 1100) | 1101 | 1102 | .... | 1118 | newer

    0 0

    (EMAILWIRE.COM, November 21, 2018 ) Protein expression is a process in which proteins are synthesized, modified and regulated. Protein expression involves laboratory techniques & procedures which aid in manufacture of proteins. The technique allows to produce and purify the desired protein, either inside or outside a cell. The proteins synthesized using protein expression technique can be used for industrial processes or to diagnose and to treat diseases. Protein expression provides substrates or enzymes required for further analysis.

    Get sample PDF copy @ https://www.theinsightpartners.com/sample/TIPHE100001247?nb

    The “Global Protein Expression Market Analysis to 2025” is a specialized and in-depth study of the healthcare industry with a focused global market trend. The report aims to provide an overview of global protein expressions market with detailed market segmentation by product, services, application, end user and geography. The global protein expressions market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading market players and offers key trends and opportunities in the market.

    On the basis of product, the market is segmented into competent cells, expression vectors, reagents and instruments. Based on services, the market is classified as antibody development & production, protein expression & production, hybridoma one-stop services, stable cell line development and bioanalytical assay services. By application, the market is segmented into research applications, therapeutic applications and industrial applications. Based on end user, the market is segmented into pharmaceutical & biotechnology companies, contract research organizations, academic research institutes and others.

    The report provides a detailed overview on the industry including both qualitative and quantitative information. It provides overview and forecast of the global protein expressions based on product, services, application and end user. It also provides market size and forecast till 2025 for overall protein expressions market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East &Africa (MEA) and South & Central America. The market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 13 countries globally along with current trend and opportunities prevailing in the region.

    Inquiry for Discount: https://www.theinsightpartners.com/discount/TIPHE100001247?nb

    North America is expected to dominate the protein expressions market in the global arena due to the increasing adoption rate for biotechnology based therapeutics and increasing interest of pharmaceutical companies in developing protein based medicines in the region. Moreover, the Asia-Pacific region is anticipated to show a significant growth rate during the forecast period in the global protein expressions market due to the growth of pharmaceutical and biotechnology industry in the region.


    Sameer Joshi
    +1-646-491-9876
    sam@theinsightpartners.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, November 21, 2018 ) Immunoassay is a technique used to detect presence of a particular substance in the human body that may be an antigen, antibody, pathogen, hormone, or an enzyme. Immunoassay is based on the principle of antigen and antibody specificity. Immunoassays has its application in the field of clinical chemistry. They are being widely used owing to their specificity and rapid test time. Beside clinical diagnostic, immunoassays are being widely used in field of research and development and quality control in pharmaceutical & biotechnology and food & beverages industry.

    Rising impact of infectious diseases and growing geriatric population has led to high diagnostic test volumes, aiding a trend shift towards lab automation. Technological innovation for development of impressive lab equipment will drive global automated immunoassay analyzers market.
    The "Global automated immunoassay analyzers market Analysis to 2025" is a specialized and in-depth study of the medical device industry with a focus on the global market trend. The automated immunoassay analyzers market report aims to provide an overview of global automated immunoassay analyzers market with detailed market segmentation by product, application and end user. The global automated immunoassay analyzers market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading market players and offers key trends and opportunities in the market.

    Get sample PDF copy @ https://www.theinsightpartners.com/sample/TIPHE100001315?nb

    The List of Companies

    1. Abbott Laboratories
    2. BioMerieux
    3. F. Hoffmann-La Roche Ltd
    4. Becton Dickinson and Company
    5. Biokit
    6. Carolina Liquid Chemistries Corporation
    7. Inova Diagnostics
    8. Luminex Corporation
    9. Meril Life Sciences Pvt. Ltd.
    10. Ortho Clinical Diagnostics

    The global automated immunoassay analyzers market is segmented on the basis of product, application and end user. The product segment includes, immunofluorescence, chemiluminescence, ELISA, enzyme linked fluorescent system, multiplexed assay system and radioimmunoassay. Based on application, the market is segmented as, infectious diseases, endocrinology, drug monitoring, cardiology, oncology and allergy testing. Based on end user, the market is classified as, hospitals, diagnostic laboratories, research and academic laboratories, pharmaceutical & biotechnology companies and others.

    Inquiry for Discount: https://www.theinsightpartners.com/discount/TIPHE100001315?nb

    The automated immunoassay analyzers market report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global automated immunoassay analyzers market based on product, application and end user. It also provides market size and forecast till 2025 for overall automated immunoassay analyzers market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 13 counties globally along with current trend and opportunities prevailing in the region.


    Sameer Joshi
    +1-646-491-9876
    sam@theinsightpartners.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, November 21, 2018 ) Biopreservation is the use of natural or controlled microbiota or antimicrobials as a way of preserving food and extending its shelf life. Beneficial bacteria or the fermentation products produced by these bacteria are used in biopreservation to control spoilage and render pathogens inactive in food. The biopreservation especially utilizing lactic acid bacteria (LAB) that are inhibitory to food spoilage microbes, has been practiced since early ages, at first unconsciously but eventually with an increasingly robust scientific foundation. Thus, equipment such as refrigerator, freezer, liquid nitrogen and consumables.

    The biopreservation market is anticipated to grow with a significant rate in the coming years, owing to factors such as, improving healthcare expenditure increase, increased adoption of advanced technologies, and increasing the adoption of regenerative medicine will be this factors driving the market's growth during the predicted period. The emerging economies are offering huge opportunities for the players operating in the biopreservation market.

    Get sample PDF copy @ https://www.theinsightpartners.com/sample/TIPHE100001326?nb

    The "Global Biopreservation Market Analysis to 2025" is a specialized and in-depth study of the medical device industry with a focus on the global market trend. The report aims to provide an overview of global biopreservation market with detailed market segmentation by product, application, biospecimens, end user and geography. The global biopreservation market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading market players and offers key trends and opportunities in the market.

    The global biopreservation market is segmented on the basis of product, application, biospecimens, and end user. The product segment includes, biopreservation equipment and biopreservation media. The segment of biopreservation equipment is further classified into, temperature control systems, incubators, centrifuges, accessories and, other equipment. Temperature control systems again classified into freezers, refrigerators, cryogenic storage systems, thawing equipment. The segment of biopreservation media is classified into nutrient media, sera, growth factors and supplements. On application basis, the market is segmented as, therapeutic applications, research applications, clinical trials and other applications. Based on biospecimens, the market is segmented as, stem cells, organs, human tissue samples, human tissue samples and, other biospecimens. Based on end user, the market is classified as, gene bank, hospitals, biobanks and, others end users.

    Inquiry for Discount: https://www.theinsightpartners.com/discount/TIPHE100001326?nb

    The biopreservation market report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global biopreservation market based on product, application, biospecimens, and end user. It also provides market size and forecast till 2025 for overall biopreservation market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 13 counties globally along with current trend and opportunities prevailing in the region.

    North America holds largest share of biopreservation market, novel drug developments and therapies in the biomedical research. As well as to rise in number of patients suffering from chronic diseases. Rising government investments in R&D, thereby propelling demand across the region.


    Sameer Joshi
    +1-646-491-9876
    sam@theinsightpartners.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, November 24, 2018 ) Summary

    According to the recently published report 'Phosphatidylinositol 4,5 Bisphosphate 3 Kinase-Pipeline Review, H2 2018'; Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) pipeline Target constitutes close to 22 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes. 

    Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153)-The phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha also called p110α is a protein encoded by the PIK3CA gene. It is involved in cell growth, survival, proliferation, motility and morphology. It participates in cellular signaling in response to various growth factors. It is involved in the activation of AKT1 and signaling via insulin receptor substrate (IRS) proteins. It is essential in endothelial cell migration during vascular development through VEGFA signaling. It is required for lymphatic vasculature development. 

    Get a Sample Report:   https://www.reportsweb.com/inquiry&RW00012283732/sample

    The report 'Phosphatidylinositol 4,5 Bisphosphate 3 Kinase-Pipeline Review, H2 2018' outlays comprehensive information on the Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

    It also reviews key players involved in Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 3 and 10 respectively. 

    Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology and Infectious Disease which include indications Metastatic Breast Cancer, Breast Cancer, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Multiple Myeloma (Kahler Disease), Ovarian Cancer, Solid Tumor, Follicular Lymphoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Pancreatic Cancer, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Cell Carcinoma, Thyroid Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Thyroid Cancer, B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, CNS Lymphoma, Colon Cancer, Colorectal Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Gastroesophageal (GE) Junction Carcinomas, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Human Immunodeficiency Virus (HIV) Infections (AIDS), Lung Cancer, Malignant Mesothelioma, Malignant Pleural Mesothelioma, Mantle Cell Lymphoma, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Myelofibrosis, Non-Small Cell Lung Carcinoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pancreatic Ductal Adenocarcinoma, Papillary Thyroid Cancer, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary CNS Lymphoma, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Squamous Cell Carcinoma, Thrombocythemia Myelofibrosis, Thymoma (Thymic Epithelial Tumor) and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Get Interesting Discount: https://www.reportsweb.com/inquiry&RW00012283732/discount

    Scope

    -The report provides a snapshot of the global therapeutic landscape for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153)
    -The report reviews Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
    -The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
    -The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
    -The report reviews key players involved in Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics and enlists all their major and minor projects 
    -The report assesses Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
    -The report summarizes all the dormant and discontinued pipeline projects 
    -The report reviews latest news and deals related to Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics

    Reasons to buy

    -Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    -Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
    -Identify and understand the targeted therapy areas and indications for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153)
    -Identify the use of drugs for target identification and drug repurposing
    -Identify potential new clients or partners in the target demographic
    -Develop strategic initiatives by understanding the focus areas of leading companies 
    -Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    -Devise corrective measures for pipeline projects by understanding Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3CA or PIK3CA or EC 2.7.11.1 or EC 2.7.1.153) development landscape 
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

    Get More Information : https://www.reportsweb.com/inquiry&RW00012283732/buying


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, November 24, 2018 ) Summary

    According to the recently published report 'Caspase 3-Pipeline Review, H2 2018'; Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) pipeline Target constitutes close to 13 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. 

    Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56)-Caspase-3 is a caspase protein encoded by the CASP3 gene. It interacts with caspase-8 and caspase-9. It cleaves and activates sterol regulatory element binding proteins (SREBPs) between the basic helix-loop-helix leucine zipper domain and the membrane attachment domain. It cleaves and activates caspase-6,-7 and-9. It is involved in the cleavage of huntingtin. It triggers cell adhesion in sympathetic neurons through RET cleavage. 

    Get a Sample Report:   https://www.reportsweb.com/inquiry&RW00012283733/sample

    The report 'Caspase 3-Pipeline Review, H2 2018' outlays comprehensive information on the Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

    It also reviews key players involved in Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 6 and 1 respectively.

    Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Genito Urinary System And Sex Hormones, Cardiovascular, Infectious Disease, Central Nervous System, Hematological Disorders, Immunology, Metabolic Disorders, Ophthalmology, Respiratory and Toxicology which include indications Colorectal Cancer, Glomerulonephritis, Hepatocellular Carcinoma, Inflammatory Bowel Disease, Age Related Macular Degeneration, Alzheimer's Disease, Autoimmune Hepatitis, Bladder Cancer, Chemotherapy Induced Neutropenia, Diabetic Retinopathy, Febrile Neutropenia, Glioblastoma Multiforme (GBM), Hepatitis C, Liver Cirrhosis, Liver Failure (Hepatic Insufficiency), Liver Fibrosis, Liver Transplant Rejection, Metastatic Brain Tumor, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Myocardial Infarction, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Parkinson's Disease, Portal Hypertension, Primary Sclerosing Cholangitis, Prostate Cancer, Pulmonary Fibrosis, Renal Failure, Small-Cell Lung Cancer, Solid Tumor, Spinal Cord Injury, Stroke, Traumatic Brain Injury and Zika Virus Infections.

    Get Interesting Discount: https://www.reportsweb.com/inquiry&RW00012283733/discount

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The report provides a snapshot of the global therapeutic landscape for Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56)
    -The report reviews Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
    -The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
    -The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
    -The report reviews key players involved in Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics and enlists all their major and minor projects 
    -The report assesses Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
    -The report summarizes all the dormant and discontinued pipeline projects 
    -The report reviews latest news and deals related to Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics

    Reasons to buy

    -Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    -Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
    -Identify and understand the targeted therapy areas and indications for Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56)
    -Identify the use of drugs for target identification and drug repurposing
    -Identify potential new clients or partners in the target demographic
    -Develop strategic initiatives by understanding the focus areas of leading companies 
    -Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    -Devise corrective measures for pipeline projects by understanding Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) development landscape 
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

    Get More Information : https://www.reportsweb.com/inquiry&RW00012283733/buying


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, November 24, 2018 ) Summary

    According to the recently published report 'Lysosomal Alpha Glucosidase-Pipeline Review, H2 2018'; Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) pipeline Target constitutes close to 16 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. 

    Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20)-Lysosomal alpha-glucosidase is an enzyme encoded by the GAA gene. It is essential for the degradation of glygogen to glucose in lysosomes. Defects in this gene lead to glycogen storage disease II or Pompe disease. 

    The report 'Lysosomal Alpha Glucosidase-Pipeline Review, H2 2018' outlays comprehensive information on the Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

    Get a Sample Report:   https://www.reportsweb.com/inquiry&RW00012283735/sample

    It also reviews key players involved in Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 2, 1, 1 and 8 respectively. Similarly, the universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders which include indications Pompe Disease.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Get Interesting Discount:  https://www.reportsweb.com/inquiry&RW00012283735/discount

    Scope

    -The report provides a snapshot of the global therapeutic landscape for Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20)
    -The report reviews Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
    -The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
    -The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
    -The report reviews key players involved in Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) targeted therapeutics and enlists all their major and minor projects 
    -The report assesses Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
    -The report summarizes all the dormant and discontinued pipeline projects 
    -The report reviews latest news and deals related to Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) targeted therapeutics

    Reasons to buy

    -Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    -Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
    -Identify and understand the targeted therapy areas and indications for Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20)
    -Identify the use of drugs for target identification and drug repurposing
    -Identify potential new clients or partners in the target demographic
    -Develop strategic initiatives by understanding the focus areas of leading companies 
    -Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    -Devise corrective measures for pipeline projects by understanding Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) development landscape 
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

    Get More Information : https://www.reportsweb.com/inquiry&RW00012283735/buying


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, November 24, 2018 ) Summary

    Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46)-Beta-secretase 1 (BACE1) is an enzyme that in humans is encoded by the BACE1 gene. It is responsible for the proteolytic processing of the amyloid precursor protein (APP). It cleaves at the N-terminus of the A-beta peptide sequence of APP. This leads to the generation and extracellular release of beta-cleaved soluble APP and a corresponding cell-associated C-terminal fragment which is later released by gamma-secretase. 

    Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) pipeline Target constitutes close to 18 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 2, 1 and 7 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 4 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Alzheimer's Disease, Dementia Associated With Alzheimer's Disease and Mild Cognitive Impairment. 

    Get a Sample Report:  https://www.reportsweb.com/inquiry&RW00012283736/sample

    The latest report Beta Secretase 1-Pipeline Review, H2 2018, outlays comprehensive information on the Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Get Interesting Discount:  https://www.reportsweb.com/inquiry&RW00012283736/discount

    Scope

    -The report provides a snapshot of the global therapeutic landscape for Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46)
    -The report reviews Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
    -The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
    -The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
    -The report reviews key players involved in Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics and enlists all their major and minor projects 
    -The report assesses Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
    -The report summarizes all the dormant and discontinued pipeline projects 
    -The report reviews latest news and deals related to Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics

    Reasons to buy

    -Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    -Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
    -Identify and understand the targeted therapy areas and indications for Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46)
    -Identify the use of drugs for target identification and drug repurposing
    -Identify potential new clients or partners in the target demographic
    -Develop strategic initiatives by understanding the focus areas of leading companies 
    -Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    -Devise corrective measures for pipeline projects by understanding Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) development landscape 
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

    Get More Information : https://www.reportsweb.com/inquiry&RW00012283736/buying


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, November 24, 2018 ) Summary

    Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2)-Transforming growth factor beta 2 (TGF-β2) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB2 gene. It regulates proliferation, differentiation, adhesion and migration. It has suppressive effects on interleukin-2 dependent T-cell growth. 

    Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Ophthalmology, Dermatology, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones, Metabolic Disorders, Musculoskeletal Disorders and Respiratory which include indications Glioblastoma Multiforme (GBM), Open-Angle Glaucoma, Age Related Macular Degeneration, Choroidal Neovascularization, Diabetic Macular Edema, Fibrosis, Head And Neck Cancer, Idiopathic Pulmonary Fibrosis, Kidney Fibrosis, Liver Fibrosis, Melanoma, Metastatic Breast Cancer, Metastatic Lung Cancer, Non-Small Cell Lung Cancer, Osteogenesis Imperfecta, Pancreatic Cancer, Proliferative Vitreoretinopathy (PVR) and Scar. 

    Get a Sample Report:   https://www.reportsweb.com/inquiry&RW00012283738/sample

    The latest report Transforming Growth Factor Beta 2-Pipeline Review, H2 2018, outlays comprehensive information on the Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Get Interesting Discount: https://www.reportsweb.com/inquiry&RW00012283738/discount

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The report provides a snapshot of the global therapeutic landscape for Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2)
    -The report reviews Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
    -The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
    -The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
    -The report reviews key players involved in Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics and enlists all their major and minor projects 
    -The report assesses Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
    -The report summarizes all the dormant and discontinued pipeline projects 
    -The report reviews latest news and deals related to Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics

    Reasons to buy

    -Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    -Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
    -Identify and understand the targeted therapy areas and indications for Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2)
    -Identify the use of drugs for target identification and drug repurposing
    -Identify potential new clients or partners in the target demographic
    -Develop strategic initiatives by understanding the focus areas of leading companies 
    -Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    -Devise corrective measures for pipeline projects by understanding Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) development landscape 
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

    Get More Information : https://www.reportsweb.com/inquiry&RW00012283738/buying


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, November 24, 2018 ) Summary

    Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) pipeline Target constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Phosphatidylinositol 4,5 Bisphosphate 3 Kinase-Pipeline Review, H2 2018, outlays comprehensive information on the Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

    Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153)-Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit beta isoform is an enzyme encoded by the PIK3CB gene. It is involved in cell growth, survival, proliferation, motility and morphology. It participates in cellular signaling in response to various growth factors. It is involved in the activation of AKT1 and signaling via insulin-receptor substrate (IRS) proteins. It is required for lymphatic vasculature development, different signaling pathways for stable platelet adhesion and aggregation. It plays an important role in platelet activation.

    Get a Sample Report:    https://www.reportsweb.com/inquiry&RW00012283739/sample


    The molecules developed by companies in Phase II, Phase I and Preclinical stages are 5, 2 and 7 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Dermatology and Infectious Disease which include indications Solid Tumor, Breast Cancer, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Ovarian Cancer, Prostate Cancer, Follicular Lymphoma, Glioblastoma Multiforme (GBM), Head And Neck Cancer Squamous Cell Carcinoma, Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Multiple Myeloma (Kahler Disease), Neuroblastoma, Pancreatic Cancer, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Thyroid Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma, Anaplastic Thyroid Cancer, Burkitt Lymphoma, CNS Lymphoma, Colorectal Cancer, Epithelial Ovarian Cancer, Gastric Cancer, Gastrointestinal Stromal Tumor (GIST), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Human Immunodeficiency Virus (HIV) Infections (AIDS), Lung Cancer, Mantle Cell Lymphoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Myelofibrosis, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Papillary Thyroid Cancer, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary CNS Lymphoma, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Squamous Non-Small Cell Lung Cancer, Thrombocythemia Myelofibrosis, Thrombosis, Thymoma (Thymic Epithelial Tumor) and Unspecified B-Cell Lymphomas. 

    Furthermore, this report also reviews key players involved in Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Get Interesting Discount:  https://www.reportsweb.com/inquiry&RW00012283739/discount


    Scope

    -The report provides a snapshot of the global therapeutic landscape for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153)
    -The report reviews Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
    -The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
    -The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
    -The report reviews key players involved in Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) targeted therapeutics and enlists all their major and minor projects 
    -The report assesses Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
    -The report summarizes all the dormant and discontinued pipeline projects 
    -The report reviews latest news and deals related to Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) targeted therapeutics

    Reasons to buy

    -Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    -Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
    -Identify and understand the targeted therapy areas and indications for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153)
    -Identify the use of drugs for target identification and drug repurposing
    -Identify potential new clients or partners in the target demographic
    -Develop strategic initiatives by understanding the focus areas of leading companies 
    -Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    -Devise corrective measures for pipeline projects by understanding Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) development landscape 
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

    Get More Information : https://www.reportsweb.com/inquiry&RW00012283739/buying


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, November 24, 2018 ) Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers-Pipeline Review, H2 2018, provides an overview of the Diabetic Foot Ulcers (Metabolic Disorders) pipeline landscape.

    Diabetic foot ulcers are sores that occur on the feet of people with Type 1 Diabetes and Type 2 Diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg, pain, walking with difficulty, discoloration in feet: black, blue, or red, cold feet and fever, skin redness or swelling, or other signs of infection. The predisposing factors include diabetic neuropathy, peripheral vascular disease, a foot deformity and history of tobacco use disorder. 

    Get a Sample Report:   https://www.reportsweb.com/inquiry&RW00012326268/sample

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Diabetic Foot Ulcers-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 12, 9, 1, 16, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


    Get Interesting Discount: https://www.reportsweb.com/inquiry&RW00012326268/discount

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers (Metabolic Disorders).
    -The pipeline guide reviews pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
    -The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    -The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    -The pipeline guide reviews key companies involved in Diabetic Foot Ulcers (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
    -The pipeline guide evaluates Diabetic Foot Ulcers (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    -The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
    -The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders)

    Reasons to buy

    -Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    -Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    -Find and recognize significant and varied types of therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders).
    -Classify potential new clients or partners in the target demographic.
    -Develop tactical initiatives by understanding the focus areas of leading companies.
    -Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    -Formulate corrective measures for pipeline projects by understanding Diabetic Foot Ulcers (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    -Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

    Get More Information : https://www.reportsweb.com/inquiry&RW00012326268/buying


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, November 24, 2018 ) Diabetic Neuropathy-Pipeline Review, H2 2018

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Neuropathy-Pipeline Review, H2 2018, provides an overview of the Diabetic Neuropathy (Metabolic Disorders) pipeline landscape.

    Diabetic neuropathy, a common complication of diabetes, is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning and pain. The predisposing factors are obesity, hypertension, high lipid and sugar levels, smoking, etc. It may be managed by medication and dietary modification. 

    Get a Sample Report:   https://www.reportsweb.com/inquiry&RW00012326269/sample

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Diabetic Neuropathy-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Diabetic Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Diabetic Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 10, 6, 15 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

    Diabetic Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Get Interesting Discount: https://www.reportsweb.com/inquiry&RW00012326269/discount

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy (Metabolic Disorders).
    -The pipeline guide reviews pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
    -The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    -The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    -The pipeline guide reviews key companies involved in Diabetic Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
    -The pipeline guide evaluates Diabetic Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    -The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
    -The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders)

    Reasons to buy

    -Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    -Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    -Find and recognize significant and varied types of therapeutics under development for Diabetic Neuropathy (Metabolic Disorders).
    -Classify potential new clients or partners in the target demographic.
    -Develop tactical initiatives by understanding the focus areas of leading companies.
    -Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    -Formulate corrective measures for pipeline projects by understanding Diabetic Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    -Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

    Get More Information : https://www.reportsweb.com/inquiry&RW00012326269/buying


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

    (EMAILWIRE.COM, November 24, 2018 ) Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Radiodermatitis-Pipeline Review, H2 2018, provides an overview of the Radiodermatitis (Toxicology) pipeline landscape.

    Radiodermatitis is an inflammation of the skin caused by radiation. Several factors can be attributed to the varying response of patients' skin to radiation therapy such as treatment-related factors such as individual fraction size, type of energy, and the use of bolus doses can impact skin reactions. Host factors also may play a role in the development of radiodermatitis; they include genetic factors, personal factors, existing skin integrity issues, comorbid conditions, nutritional status, age, race and ethnicity, medications, sun exposure, smoking, and mobility. 

    Get a Sample Report:   https://www.reportsweb.com/inquiry&RW00012326270/sample

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Radiodermatitis-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Radiodermatitis (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Radiodermatitis (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiodermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I and Preclinical stages are 1, 1 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Radiodermatitis (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Get Interesting Discount:  https://www.reportsweb.com/inquiry&RW00012326270/discount

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The pipeline guide provides a snapshot of the global therapeutic landscape of Radiodermatitis (Toxicology).
    -The pipeline guide reviews pipeline therapeutics for Radiodermatitis (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
    -The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    -The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    -The pipeline guide reviews key companies involved in Radiodermatitis (Toxicology) therapeutics and enlists all their major and minor projects.
    -The pipeline guide evaluates Radiodermatitis (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    -The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
    -The pipeline guide reviews latest news related to pipeline therapeutics for Radiodermatitis (Toxicology)

    Reasons to buy

    -Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    -Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    -Find and recognize significant and varied types of therapeutics under development for Radiodermatitis (Toxicology).
    -Classify potential new clients or partners in the target demographic.
    -Develop tactical initiatives by understanding the focus areas of leading companies.
    -Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    -Formulate corrective measures for pipeline projects by understanding Radiodermatitis (Toxicology) pipeline depth and focus of Indication therapeutics.
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    -Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

    Get More Information : https://www.reportsweb.com/inquiry&RW00012326270/buying


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, November 24, 2018 ) Summary

    Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report SerineThreonine Protein Kinase Pim 1-Pipeline Review, H2 2018, outlays comprehensive information on the Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

    Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1)-Proto-oncogene serine/threonine-protein kinase Pim-1 is an enzyme encoded by the PIM1 gene. It promotes cell cycle progression and tumorigenesis by down-regulating expression of a regulator of cell cycle progression CDKN1B at both transcriptional and post-translational levels.

    Get a Sample Report:   https://www.reportsweb.com/inquiry&RW00012326271/sample

    It mediates survival signaling through phosphorylation of BAD which induces release of the anti-apoptotic protein Bcl-X (L)/BCL2L1. It phosphorylation of MAP3K5, another proapoptotic protein by PIM1 significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 7 and 3 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular and Immunology which include indications Prostate Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Chronic Lymphocytic Leukemia (CLL), Bladder Cancer, Diffuse Large B-Cell Lymphoma, Hematological Tumor, Lymphoma, Myocardial Infarction, Non-Small Cell Lung Carcinoma, Pancreatic Cancer, Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Solid Tumor and Transitional Cell Carcinoma (Urothelial Cell Carcinoma). 

    Furthermore, this report also reviews key players involved in Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Get Interesting Discount:  https://www.reportsweb.com/inquiry&RW00012326271/discount

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1)
    -The report reviews Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
    -The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
    -The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
    -The report reviews key players involved in Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects 
    -The report assesses Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
    -The report summarizes all the dormant and discontinued pipeline projects 
    -The report reviews latest news and deals related to Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics

    Reasons to buy

    -Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    -Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
    -Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1)Identify the use of drugs for target identification and drug repurposing
    -Identify potential new clients or partners in the target demographic
    -Develop strategic initiatives by understanding the focus areas of leading companies 
    -Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    -Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) development landscape 
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

    Get More Information : https://www.reportsweb.com/inquiry&RW00012326271/buying


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, November 24, 2018 ) Summary

    High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1)-Tropomyosin receptor kinase A or High Affinity Nerve Growth Factor Receptor is a protein encoded by the NTRK1 gene. High affinity receptor for NGF bind and be activated by NTF3/neurotrophin-3. Upon dimeric NGF ligand-binding undergoes homodimerization, autophosphorylation and activation. It phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades driving cell survival and differentiation. 

    High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) pipeline Target constitutes close to 24 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes.

    Get a Sample Report:   https://www.reportsweb.com/inquiry&RW00012326272/sample

    The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 3, 8 and 3 respectively. Similarly, the universities portfolio in IND/CTA Filed and Preclinical stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Immunology, Dermatology, Genetic Disorders, Metabolic Disorders and Ophthalmology which include indications Colorectal Cancer, Solid Tumor, Non-Small Cell Lung Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alzheimer's Disease, Breast Cancer, Inflammatory Pain, Osteoarthritis Pain, Pain, Pancreatic Cancer, Amyotrophic Lateral Sclerosis, Bile Duct Cancer (Cholangiocarcinoma), Central Nervous System (CNS) Tumor, Fibrosarcoma, Neuroblastoma, Pruritus, Salivary Gland Cancer, Thymic Carcinoma, Anaplastic Large Cell Lymphoma (ALCL), Astrocytoma, Atopic Dermatitis (Atopic Eczema), Basal Cell Carcinoma (Basal Cell Epithelioma), Biliary Tumor, Bladder Cancer, Brain Tumor, Cancer Pain, Cervical Cancer, Diabetic Retinopathy, Gastric Cancer, Gastrointestinal Stromal Tumor (GIST), Glioma, Head And Neck Cancer, Hepatocellular Carcinoma, Inflammation, Keratoconjunctivitis Sicca (Dry Eye), Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis), Low Back Pain, Lymphoma, Melanoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Metastatic Pancreatic Cancer, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Neuroendocrine Tumors, Neuropathic Pain (Neuralgia), Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, Open-Angle Glaucoma, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Papillary Thyroid Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis, Renal Cell Carcinoma, Retinitis Pigmentosa (Retinitis), Sarcomas, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Synovial Sarcoma, Thymoma (Thymic Epithelial Tumor) and Thyroid Cancer. 

    The latest report High Affinity Nerve Growth Factor Receptor-Pipeline Review, H2 2018, outlays comprehensive information on the High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Get Interesting Discount:  https://www.reportsweb.com/inquiry&RW00012326272/discount

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The report provides a snapshot of the global therapeutic landscape for High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1)
    -The report reviews High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
    -The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
    -The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
    -The report reviews key players involved in High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects 
    -The report assesses High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
    -The report summarizes all the dormant and discontinued pipeline projects 
    -The report reviews latest news and deals related to High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics

    Reasons to buy

    -Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    -Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
    -Identify and understand the targeted therapy areas and indications for High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1)Identify the use of drugs for target identification and drug repurposing
    -Identify potential new clients or partners in the target demographic
    -Develop strategic initiatives by understanding the focus areas of leading companies 
    -Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    -Devise corrective measures for pipeline projects by understanding High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) development landscape 
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

    Get More Information : https://www.reportsweb.com/inquiry&RW00012326272/buying


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, November 24, 2018 ) Summary

    According to the recently published report 'SerineThreonine Protein Kinase Pim 3-Pipeline Review, H2 2018'; Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. 

    Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1)-Serine/threonine-protein kinase Pim-3 is an enzyme encoded by the PIM3. It prevents apoptosis. It contribute to tumorigenesis through the delivery of survival signaling through phosphorylation of BAD which induces release of the anti-apoptotic protein Bcl-X(L), by regulation of cell cycle progression, protein synthesis and by regulation of MYC transcriptional activity. 

    The report 'SerineThreonine Protein Kinase Pim 3-Pipeline Review, H2 2018' outlays comprehensive information on the Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

    Get a Sample Report:   https://www.reportsweb.com/inquiry&RW00012326273/sample

    It also reviews key players involved in Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 4 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively.

    Report covers products from therapy areas Oncology and Immunology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Chronic Lymphocytic Leukemia (CLL), Bladder Cancer, Diffuse Large B-Cell Lymphoma, Hematological Tumor, Lymphoma, Non-Small Cell Lung Carcinoma, Pancreatic Cancer, Prostate Cancer, Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Solid Tumor and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Get Interesting Discount: https://www.reportsweb.com/inquiry&RW00012326273/discount

    Scope

    -The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1)
    -The report reviews Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
    -The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
    -The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
    -The report reviews key players involved in Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects 
    -The report assesses Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
    -The report summarizes all the dormant and discontinued pipeline projects 
    -The report reviews latest news and deals related to Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) targeted therapeutics

    Reasons to buy

    -Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    -Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
    -Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1)Identify the use of drugs for target identification and drug repurposing
    -Identify potential new clients or partners in the target demographic
    -Develop strategic initiatives by understanding the focus areas of leading companies 
    -Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    -Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) development landscape 
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

    Get More Information : https://www.reportsweb.com/inquiry&RW00012326273/buying




    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, November 24, 2018 ) Summary

    According to the recently published report 'Cyclin Dependent Kinase 9-Pipeline Review, H2 2018'; Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) pipeline Target constitutes close to 27 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes. 

    Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23)-Cyclin-dependent kinase 9 (CDK9) is a cyclin-dependent kinase associated with P-TEFb. This kinase was found to be a component of the multiprotein complex TAK/P-TEFb, which is an elongation factor for RNA polymerase II-directed transcription and functions by phosphorylating the C-terminal domain of the largest subunit of RNA polymerase II. This protein forms a complex with and is regulated by its regulatory subunit cyclin T or cyclin K. HIV-1 Tat protein was found to interact with CDK9 and cyclin T, which suggested a possible involvement of this protein in AIDS. 

    Get a Sample Report:   https://www.reportsweb.com/inquiry&RW00012326274/sample

    The report 'Cyclin Dependent Kinase 9-Pipeline Review, H2 2018' outlays comprehensive information on the Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

    It also reviews key players involved in Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 7, 7 and 2 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively.

    Report covers products from therapy areas Oncology, Infectious Disease, Immunology, Metabolic Disorders and Respiratory which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Ovarian Cancer, Chronic Lymphocytic Leukemia (CLL), Lung Cancer, Pancreatic Cancer, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Diffuse Large B-Cell Lymphoma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Mantle Cell Lymphoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Neuroblastoma, Non-Hodgkin Lymphoma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, AIDS-Related Cancer, Anaplastic Astrocytoma, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Blood Cancer, Cystic Fibrosis, Epstein-Barr Virus (HHV-4) Infections, Follicular Lymphoma, Glioblastoma Multiforme (GBM), Gliosarcoma, Hepatitis B, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Inflammation, Laryngeal Cancer, Leukemias, Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Hepatocellular Carcinoma (HCC), Pituitary ACTH Hypersecretion (Cushing Disease), Prostate Cancer, Pseudomonas aeruginosa Infections, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rheumatoid Arthritis, Simplexvirus (HSV) Infections, Uterine Cancer and Warts.

    Get Interesting Discount:  https://www.reportsweb.com/inquiry&RW00012326274/discount

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23)
    -The report reviews Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
    -The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
    -The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
    -The report reviews key players involved in Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics and enlists all their major and minor projects 
    -The report assesses Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
    -The report summarizes all the dormant and discontinued pipeline projects 
    -The report reviews latest news and deals related to Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics

    Reasons to buy

    -Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    -Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
    -Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23)Identify the use of drugs for target identification and drug repurposing
    -Identify potential new clients or partners in the target demographic
    -Develop strategic initiatives by understanding the focus areas of leading companies 
    -Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    -Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) development landscape 
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 

    Get More Information : https://www.reportsweb.com/inquiry&RW00012326274/buying


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, November 24, 2018 ) Summary

    Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1)-Serine/threonine-protein kinase Pim-2 is an enzyme encoded by the PIM2. It is involved in cell survival and cell proliferation. It regulates cap-dependent protein translation in a mammalian target of rapamycin complex 1 (mTORC1)-independent manner and in parallel to the PI3K-Akt pathway. It mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl-X (L)/BCL2L1. It promotes cell survival in response to a variety of proliferative signals via positive regulation of the I-kappa-B kinase/NF-kappa-B cascade. 

    Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) pipeline Target constitutes close to 8 molecules. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 6 and 1 respectively. Report covers products from therapy areas Oncology and Immunology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Chronic Lymphocytic Leukemia (CLL), Pancreatic Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Bladder Cancer, Breast Cancer, Colon Cancer, Diffuse Large B-Cell Lymphoma, Hematological Tumor, Liver Cancer, Lung Cancer, Lymphoma, Non-Small Cell Lung Carcinoma, Prostate Cancer, Psoriasis, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Solid Tumor and Transitional Cell Carcinoma (Urothelial Cell Carcinoma). 

    Get a Sample Report:   https://www.reportsweb.com/inquiry&RW00012326275/sample

    The latest report SerineThreonine Protein Kinase Pim 2-Pipeline Review, H2 2018, outlays comprehensive information on the Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Get Interesting Discount:  https://www.reportsweb.com/inquiry&RW00012326275/discount

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1)
    -The report reviews Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
    -The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
    -The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
    -The report reviews key players involved in Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects 
    -The report assesses Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
    -The report summarizes all the dormant and discontinued pipeline projects 
    -The report reviews latest news and deals related to Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics

    Reasons to buy

    -Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    -Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
    -Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1)Identify the use of drugs for target identification and drug repurposing
    -Identify potential new clients or partners in the target demographic
    -Develop strategic initiatives by understanding the focus areas of leading companies 
    -Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    -Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) development landscape 
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 

    Get More Information : https://www.reportsweb.com/inquiry&RW00012326275/buying


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, November 24, 2018 ) Summary

    Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Histone Deacetylase 4-Pipeline Review, H2 2018, outlays comprehensive information on the Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

    Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)-Histone deacetylase 4 (HDAC4) is a protein encoded by the HDAC4 gene. It is responsible for the deacetylation of lysine residues on the N-terminal part of the core histones. It plays an important role in transcriptional regulation, cell cycle progression and developmental events. It acts via the formation of large multiprotein complexes. The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 2 and 2 respectively. 

    Get a Sample Report:    https://www.reportsweb.com/inquiry&RW00012326276/sample

    Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Cardiovascular which include indications Non-Small Cell Lung Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colon Cancer, Congestive Heart Failure (Heart Failure), Cutaneous T-Cell Lymphoma, Essential Thrombocythemia, Gallbladder Cancer, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Liver Cancer, Lung Cancer, Mycosis Fungoides, Myelodysplastic Syndrome, Pancreatic Cancer, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Prostate Cancer and Sezary Syndrome. 

    Furthermore, this report also reviews key players involved in Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Get Interesting Discount:  https://www.reportsweb.com/inquiry&RW00012326276/discount

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)
    -The report reviews Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
    -The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
    -The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
    -The report reviews key players involved in Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects 
    -The report assesses Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
    -The report summarizes all the dormant and discontinued pipeline projects 
    -The report reviews latest news and deals related to Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics

    Reasons to buy

    -Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    -Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
    -Identify and understand the targeted therapy areas and indications for Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)Identify the use of drugs for target identification and drug repurposing
    -Identify potential new clients or partners in the target demographic
    -Develop strategic initiatives by understanding the focus areas of leading companies 
    -Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    -Devise corrective measures for pipeline projects by understanding Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) development landscape 
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

    Get More Information : https://www.reportsweb.com/inquiry&RW00012326276/buying


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, November 24, 2018 ) Summary

    Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1)-Phenylalanine 4 hydroxylase or Phenylalanine hydroxylase (PAH) is an enzyme that catalyzes the hydroxylation of the aromatic side-chain of phenylalanine to generate tyrosine. The enzyme works with a molecule called tetrahydrobiopterin (BH4) to carry out this chemical reaction. Tyrosine is used to make several types of hormones, certain chemicals that transmit signals in the brain (neurotransmitters), and a pigment called melanin, which gives hair and skin their color. 

    Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) pipeline Target constitutes close to 9 molecules. The molecules developed by companies in Phase I and Preclinical stages are 1 and 8 respectively. Report covers products from therapy areas Metabolic Disorders which include indications Phenylketonuria (PKU). 

    Get a Sample Report:    https://www.reportsweb.com/inquiry&RW00012326277/sample

    The latest report Phenylalanine 4 Hydroxylase-Pipeline Review, H2 2018, outlays comprehensive information on the Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Get Interesting Discount:  https://www.reportsweb.com/inquiry&RW00012326277/discount

    Scope

    -The report provides a snapshot of the global therapeutic landscape for Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1)
    -The report reviews Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
    -The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
    -The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
    -The report reviews key players involved in Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) targeted therapeutics and enlists all their major and minor projects 
    -The report assesses Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
    -The report summarizes all the dormant and discontinued pipeline projects 
    -The report reviews latest news and deals related to Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) targeted therapeutics

    Reasons to buy

    -Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    -Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
    -Identify and understand the targeted therapy areas and indications for Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1)Identify the use of drugs for target identification and drug repurposing
    -Identify potential new clients or partners in the target demographic
    -Develop strategic initiatives by understanding the focus areas of leading companies 
    -Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    -Devise corrective measures for pipeline projects by understanding Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) development landscape 
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

    Get More Information : https://www.reportsweb.com/inquiry&RW00012326277/buying


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

    0 0

     



    (EMAILWIRE.COM, November 24, 2018 ) Summary

    Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) pipeline Target constitutes close to 21 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The latest report Integrin Beta 1-Pipeline Review, H2 2018, outlays comprehensive information on the Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

    Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1)-Integrin beta-1 also known as CD29 is a protein encoded by the ITGB1 gene. It is involved in up-regulation of the activity of kinases such as PKC via binding to KRT1. It plays a mechanistic adhesive role during telophase. Integrin alpha-3/beta-1 provides a docking site for FAP at invadopodia plasma membranes in a collagen-dependent manner and participates in the adhesion, formation of invadopodia and matrix degradation processes, promoting cell invasion.

    Get a Sample Report:   https://www.reportsweb.com/inquiry&RW00012326278/sample

    The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 11 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Musculoskeletal Disorders, Genetic Disorders, Oncology, Ophthalmology, Immunology, Cardiovascular, Gastrointestinal, Infectious Disease and Respiratory which include indications Muscular Dystrophy, Duchenne Muscular Dystrophy, Rheumatoid Arthritis, Wet (Neovascular / Exudative) Macular Degeneration, Arterial Thrombosis, Breast Cancer, Ebolavirus Infections (Ebola Hemorrhagic Fever), Fibrosis, Idiopathic Pulmonary Fibrosis, Keratoconjunctivitis Sicca (Dry Eye), Liver Fibrosis, Metastatic Melanoma, Prostate Cancer and Solid Tumor. 

    Furthermore, this report also reviews key players involved in Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Get Interesting Discount:  https://www.reportsweb.com/inquiry&RW00012326278/discount

    Scope

    -The report provides a snapshot of the global therapeutic landscape for Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1)
    -The report reviews Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
    -The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
    -The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
    -The report reviews key players involved in Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics and enlists all their major and minor projects 
    -The report assesses Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
    -The report summarizes all the dormant and discontinued pipeline projects 
    -The report reviews latest news and deals related to Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics

    Reasons to buy

    -Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    -Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
    -Identify and understand the targeted therapy areas and indications for Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1)Identify the use of drugs for target identification and drug repurposing
    -Identify potential new clients or partners in the target demographic
    -Develop strategic initiatives by understanding the focus areas of leading companies 
    -Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    -Devise corrective measures for pipeline projects by understanding Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) development landscape 
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

    Get More Information : https://www.reportsweb.com/inquiry&RW00012326278/buying


    Rajat Sahni
    +1-646-491-9876
    sales@reportsweb.com

    Source: EmailWire.Com

older | 1 | .... | 1098 | 1099 | (Page 1100) | 1101 | 1102 | .... | 1118 | newer